2.03

0.73% -0.02

Allogene Therapeutics Inc (ALLO)

Overview News Price History Option Chain Financials Discussions Forecast

Allogene Therapeutics Inc stock is traded at $2.03, with a volume of 534.25K. It is down -0.73% in the last 24 hours and down -27.32% over the past month. Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, primarily generated from collaborations and licensing agreements, supports their research and development efforts.

Previous Close:

$2.05

Open:

$2.06

24h Volume:

534.25K

Relative Volume:

0.26

Market Cap:

$444.50M

Revenue:

$95,000

Net Income/Loss:

$-327.27M

P/E Ratio:

-0.8286

EPS:

-2.45

Net Cash Flow:

$-239.25M

1W Performance:

-17.28%

1M Performance:

-27.32%

6M Performance:

-24.35%

1Y Performance:

-27.84%

1-Day Range:

$2.005

$2.095

1-Week Range:

$1.99

$2.52

52-Week Range:

$1.99

$5.775

Allogene Therapeutics Inc Stock (ALLO) Company Profile

Name

Allogene Therapeutics Inc

Sector

Healthcare (1195)

Industry

Biotechnology (683)

Phone

(650) 457-2700

Address

210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO

Employee

361

Twitter

@AllogeneTx

Next Earnings Date

2024-11-07

Latest SEC Filings

ALLO's Discussions on Twitter

Compare ALLO with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ALLO	2.03	444.50M	95,000	-327.27M	-239.25M	-2.45
VRTX	446.35	115.74B	10.63B	-479.80M	-1.35B	13.33
REGN	740.93	81.65B	13.85B	4.65B	3.32B	35.06
ARGX	589.43	34.86B	1.86B	-40.29M	-1.28B	-4.16
ALNY	249.82	32.09B	2.09B	-332.26M	16.06M	-4.14
BNTX	103.80	24.49B	3.30B	-501.07M	1.03B	11.54

Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-05-24	Downgrade	Guggenheim	Buy → Neutral
Jan-05-24	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Dec-08-23	Initiated	Citigroup	Buy
Jun-26-23	Resumed	Oppenheimer	Outperform
Mar-21-23	Initiated	Bernstein	Mkt Perform
Jan-24-23	Upgrade	JP Morgan	Neutral → Overweight
Jan-06-23	Upgrade	Robert W. Baird	Neutral → Outperform
Dec-12-22	Downgrade	BofA Securities	Buy → Underperform
Aug-10-22	Downgrade	Raymond James	Outperform → Mkt Perform
Jul-15-22	Upgrade	Goldman	Neutral → Buy
Jun-03-22	Initiated	Robert W. Baird	Neutral
Feb-28-22	Reiterated	B. Riley Securities	Buy
Oct-20-21	Initiated	Cowen	Outperform
Oct-08-21	Downgrade	Goldman	Buy → Neutral
Oct-08-21	Downgrade	Stifel	Buy → Hold
Sep-23-21	Upgrade	Raymond James	Mkt Perform → Outperform
Jun-21-21	Resumed	Jefferies	Buy
May-20-21	Upgrade	Truist	Hold → Buy
May-14-21	Initiated	B. Riley Securities	Buy
Jan-26-21	Upgrade	Stifel	Hold → Buy
Dec-10-20	Resumed	H.C. Wainwright	Buy
Nov-24-20	Initiated	BofA Securities	Buy
Oct-23-20	Initiated	RBC Capital Mkts	Outperform
Jun-01-20	Downgrade	Raymond James	Outperform → Mkt Perform
May-29-20	Reiterated	H.C. Wainwright	Buy
May-19-20	Upgrade	ROTH Capital	Neutral → Buy
May-15-20	Upgrade	Guggenheim	Neutral → Buy
May-14-20	Reiterated	H.C. Wainwright	Buy
May-14-20	Downgrade	SunTrust	Buy → Hold
Apr-13-20	Initiated	SunTrust	Buy
Mar-13-20	Initiated	H.C. Wainwright	Buy
Mar-05-20	Initiated	Stifel	Hold
Feb-24-20	Initiated	Berenberg	Hold
Dec-18-19	Initiated	JMP Securities	Mkt Outperform
Nov-04-19	Initiated	Canaccord Genuity	Buy
Aug-09-19	Initiated	BTIG Research	Buy
Jun-05-19	Initiated	ROTH Capital	Neutral
May-31-19	Initiated	Guggenheim	Neutral
May-23-19	Initiated	Stifel	Hold
Mar-29-19	Initiated	Piper Jaffray	Overweight

View All

Allogene Therapeutics Inc Stock (ALLO) Latest News

Nov 20, 2024

Allogene Therapeutics Announces Participation in December Investor Conferences - GlobeNewswire

Nov 19, 2024

Allogene Therapeutics to Present at Three Major Healthcare Conferences | ALLO Stock News - StockTitan

Nov 19, 2024

Nov 18, 2024

Allogene Therapeutics Presents Preclinical Data for - GlobeNewswire

Nov 18, 2024

Allogene's Novel Dual CAR T ALLO-329 Shows Promise in Autoimmune Disease Study | ALLO Stock News - StockTitan

Nov 18, 2024

Allogene Therapeutics, Inc Decides to Discontinue Enrollment in Its Phase 1 Cohort in the ALPHA2 Clinical Trial to Evaluate cemacabtagene ansegedleucel - Marketscreener.com

Nov 18, 2024

Short Interest in Allogene Therapeutics, Inc. (NASDAQ:ALLO) Declines By 5.8% - MarketBeat

Nov 18, 2024

Nov 15, 2024

Allogene halts enrollment in leukemia trial By Investing.com - Investing.com Australia

Nov 15, 2024

Allogene’s CAR-T ALLO-316 Demonstrates Ability to Produce Responses in Renal Cell Carcinoma, but Safety Data Includes 3 On-Study Deaths - CGTLive™

Nov 15, 2024

Nov 14, 2024

Allogene halts enrollment in leukemia trial - Investing.com

Nov 14, 2024

Allogene Therapeutics (NASDAQ:ALLO) Shares Down 6.3% on Analyst Downgrade - MarketBeat

Nov 14, 2024

Allogene Bows to BMS in Leukemia, Ending Phase I CAR T Enrollment - BioSpace

Nov 14, 2024

Piper Sandler Cuts Allogene Therapeutics (NASDAQ:ALLO) Price Target to $9.00 - MarketBeat

Nov 14, 2024

Allogene shares target cut, rating held on trial enrollment issue By Investing.com - Investing.com UK

Nov 14, 2024

Nov 12, 2024

Q3 Biotech Earnings Recap: Nkarta, Intellia, Cassava and more - BioSpace

Nov 12, 2024

Allogene Therapeutics's SWOT analysis: CAR-T pioneer's stock faces pivotal year - Investing.com India

Nov 12, 2024

Nov 10, 2024

Allogene Therapeutics Q3 2024 Earnings Preview - MSN

Nov 10, 2024

Nov 09, 2024

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 09, 2024

Nov 08, 2024

Earnings call: Allogene Therapeutics reports on CAR T therapy progress - Investing.com

Nov 08, 2024

Allogene Therapeutics (NASDAQ:ALLO) Given "Buy" Rating at HC Wainwright - MarketBeat

Nov 08, 2024